European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy
复制标题
DOI：
10.1016/j.eururo.2016.06.009
复制
发表时间：
2016-11-01
期刊：
影响因子：
23.4
通讯作者：
Bex, Axel
中科院分区：
文献类型：
--
作者：
Powles, Thomas;Staehler, Michael;Bex, Axel
欧洲泌尿外科协会肾癌指南小组建议在一种或多种血管内皮生长因子靶向治疗失败的患者中使用nivolumab和cabozantinib。最近获得的新数据显示卡博替尼的生存益处。
The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.